Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine tumor.
INTRODUCTION
Merkel cell carcinoma (MCC), or primary cutaneous neuroendocrine carcinoma, is a rare malignancy with high rates of recurrence, metastasis and mortality. The incidence of MCC has nearly tripled in the past 20 years, and is more prevalent in the immunosuppressed and elderly.
Five year overall survival from time of diagnosis is 30-64% (1, 2) . Previous studies to elucidate the molecular pathogenesis of MCC found that a subset of cases display TP53 inactivating mutations (14-28%) and/or PIK3CA activating mutations (4-17%) (1) . The discovery of Merkel cell polyomavirus (MCPyV) viral DNA via digital subtraction transcriptome analysis in a majority of MCCs represented a major breakthrough (3) . MCPyV may likely contribute to tumorigenesis via large T antigen (LTAg) inhibition of the tumor suppressor RB1, and enhanced oncoprotein gene stability and mTOR activation by small T antigen (sTAg) (1, 2) . In MCC, MCPyV displays genomic integration and characteristic truncating mutations of LTAg which render the virus replication-deficient but preserve the RB binding site (1, 3) . In contrast, oncogenic activation events in MCPyV-negative MCC have been underexplored. No targeted therapies are currently available for MCC, although survivin, PI3K, and BCL2 inhibitors may hold promise (1, 4) .
Next-generation sequencing (NGS) is a powerful, unbiased approach for identifying novel genetic aberrations in cancer, including point mutations, copy number gains/losses, gene fusions, and viral sequences (5) . Integrative sequencing incorporates data from whole exome sequencing and whole transcriptome sequencing to generate a comprehensive landscape of underlying genetic aberrations and outlier gene expression changes in tumors (5) . Recent exome sequencing studies on small cohorts of formalin-fixed, paraffin-embedded (FFPE) MCC samples identified recurrent RB1 mutations in MCPyV-negative tumors, as well as PDE4DIP mutations (6, 7) . However, NGS studies of MCC have thus far been limited, and detailed somatic mutation and expression analyses of MCC by integrative sequencing have not been reported.
The objective of the MI-ONCOSEQ precision oncology study is to carry out integrative sequencing of tumors from patients with rare or refractory disease towards the goal of identifying novel therapeutic strategies (5) . Here, we performed integrative sequencing of biospecimens obtained from two patients with MCC enrolled in MI-ONCOSEQ study as well as a validation cohort of fourteen MCC tumor samples.
METHODS

Clinical study and tumor sample procurement
Patient samples were procured and profiled under Institutional Review Board (IRB)-approved studies. For MI-ONCOSEQ samples, patients were enrolled and consented through a University of Michigan Hospital System (UMHS) IRB-approved protocol for integrative tumor sequencing, MI-ONCOSEQ (IRB#HUM00046018). Specimen collection through MI-ONCOSEQ has been previously described (5) , with tumor purity confirmed on frozen sections by the study pathologists (L.P.K. or S.A.T.). Additional samples were procured from the UMHS Cutaneous Surgery and Oncology Program Tumor Bank, as previously described (8) , with tumor purity of >70% confirmed on frozen section by the study dermatopathologists (D.R.F. or P.W.H.). For tumor bank specimens, matched normal DNA was extracted from FFPE lymph node tissue using the QIAmp FFPE DNA extraction kit. All cases showed classic MCC immunophenotype, including expression of cytokeratin-20 and neuroendocrine marker(s). Sample details including age, gender, and disease stage are summarized in Supplemental Table S1 . 
Preparation of next generation sequencing libraries
In this study we generated 59 NGS libraries to characterize a total of 16 MCC patients from two different cohorts, namely MiOncoseq index cases and the validation cohort (Supplemental Tables S1 and S2 ). Exome libraries of tumor and matched normal genomic DNA and tumor RNA were generated using the Illumina TruSeq DNA Sample Prep Kit. RNA-seq libraries were prepared according to Illumina's TruSeq RNA protocol, using 2 ug total RNA, as previously described (9) . Following standard quality control measures, libraries were analyzed by RNAseq (polyA-transcriptome), exome capture-transcriptome, and/or exome capture-genome sequencing (Supplemental Table S1 ). Paired-end libraries were sequenced with the Illumina HiSeq 2000.
Reads that passed the Illumina BaseCall software chastity filter were used for subsequent analysis. Sequence and alignment quality were assessed by FastQC and the Picard package, respectively. Whole exome library quality parameters are described in Supplemental Table S2 .
Sequencing data analyses
Paired-end whole Exome fastq sequence files generated by Illumina (2000/2500) were aligned using Novoalign multithreaded (Version 2.08.02, Novocraft) to GRCh37 genome build. Postprocessing of bam files generated by Novoalign were carried out using SAMtools (Version 0.1.19 (10) and Picard (Version 1.93). Mutational analysis was carried out on matched normaltumor pairs using VarScan2 algorithm (Version 2.3.2)(11). The vcf files for somatic mutation were created with SNV positions having base quality phred score of at least q20, 10X coverage in normal, less than 5 % allelic fraction in 1000 Genomes, and at least 10 variant reads with 2 reads in each strand in the tumor library. SNVs with > 5 recurrences reported in the Catalog of Somatic Mutations in Cancer (COSMIC) were also nominated to probe for known recurrent hotspot mutations. Indel analysis was carried out using Pindel (Version 0.2.5). Candidate indels were further filtered by the homopolymer/repeat regions, recurrent sequencing artifacts in our compendia (N=800), and high recurrence in 1000 Genome, followed by manual curation.
Nominated indels and SNV vcf's were then annotated using ANNOVAR package. Copy number aberrations were quantified and reported for each gene as the copy number ratio between each tumor and its matched normal sample, with minimum copy number ratio cutoffs of 1.25 for gains or 0.75 for losses, as previously described (12) . Copy number analysis was performed only on index cases due to high duplication rates in some libraries of the validation cohort. Tumor content was analyzed as previously described (9) .
Gene fusion and gene expression analyses were carried out using Tuxedo suite tools (Tophat 2.0.4 (13) and Bowtie [Version 0.12.8]), using the '-fusion-search' option to find candidate fusions. Nominated fusions were manually inspected for annotation and ligation artifacts.
Junction reads supporting fusion candidates were realigned using the BLAT alignment tool to confirm fusion breakpoints. Gene expression analysis was performed on the accepted_hits.bam generated by Tophat as an input for the Cufflinks (14) (Version 2.0.2) which performs assembly of transcripts and estimates abundance in the transcriptome library. In addition, 56,369 transcripts from the Ensembl resource (Ensembl 66) were used as an annotation reference to quantify expression of individual transcripts and isoforms, as previously described (9).
Unmapped sequences were used for downstream viral screening analysis using Bowtie and BLAT to align reads to all known viral genomes. Sequencing data for MIONCOSEQ cases will be deposited in dbGaP (accession: phs000673.v1.p1). Statistical comparisons of mutation rates and C>T fraction were performed using Student's t-test with Welch's correction on Graphpad Prism 6 software.
Somatic mutation validation
NOTCH1-4, PRUNE2, GRIN2A and HRAS somatic mutations were validated by Sanger sequencing at the University of Michigan Sequencing Core following PCR amplification. Due to limitations in frozen tissue availability, DNA for Sanger validation was extracted from archival FFPE tumor material for all cases except MO_1160, METMCC_862, and MCC345.
Chromatograms were visualized using Sequence Scanner 2 software.
MCPyV detection
MCPyV copy number was quantitated by LT2 (LTAg) and SET9 (sTAg) qPCR of MCC tumor DNA along with MKL-2 cell line as the standard as previously described (4, 15, 16) (Supplemental Table S1 ). One sample with extremely low viral copy number (0.0006 copies/cell) was classified as MCPyV-negative, consistent with the precedent established by the previous MCC sequencing study (6) . In cases with adequate tissue, MCPyV LTAg was detected by immunohistochemistry with CM2B4 as previously described (15) . One sample (METMCC_614) was positive for MCPyV by qPCR but negative by immunohistochemistry.
PCR-Sanger sequencing of LTAg was performed for this sample as previously described (15) which detected a tumor-specific truncating mutation; therefore, this tumor was classified as MCPyV-positive. Two patients with MCC were enrolled in the MI-ONCOSEQ precision medicine program. The first index patient (MO_1109) was a 60-year-old male who presented with MCC on the scalp that was treated with resection and adjuvant radiation therapy. After initial remission, the patient developed extensive metastatic disease that progressed despite chemotherapy. The patient was enrolled in MI-ONCOSEQ and underwent a biopsy of a chest wall metastasis (Figure 1A) . High-quality tumor RNA and DNA was subjected to NGS. There 
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unknown primary. Metastases to bone, liver, and lymph nodes were present at diagnosis. The patient progressed despite radiation therapy and chemotherapy, and was subsequently enrolled in MIONCOSEQ. Computed-tomography-guided needle biopsies were obtained from a liver metastasis ( Figure 1E) . No evidence of oncogenic viruses was detected by NGS or MCPyV qPCR, leading us to conclude that the tumor was MCPyV-negative. By CNV analysis, we detected 24 aberrations including single copy losses of RB1, TP53, and PTEN genes ( Figure 1F , Supplemental Table S4 ). Somatic mutation analysis revealed 2 PIK3CA mutations including an activation hotspot E545K, and a P146S hotspot mutation in TP53 (Supplemental Table S5 ).
Similar to MO_1109, MO_1160 also demonstrated a high mutation burden (with a total of 1441 nonsynonymous somatic mutation calls) (Supplemental Table S5 Table S3 ). In addition, lower MCPyV reads (range: 39-46) were detected in two tumors that tested negative for MCPyV by PCR and immunohistochemistry (Supplemental Table S3 ). Tumor-specific truncating LTAg mutations were not detected in mapped viral reads from these two tumors. Although this finding is of uncertain significance, the much lower number of viral reads in these two samples suggests background low level viral loads previously reported in non-MCC carcinoma, possibly representing background wild-type viral infection (19) . Based on negative qPCR and immunohistochemistry, these tumors were categorized as MCPyV-negative. Other than MCPyV, no oncogenic pathogens were identified.
Across all MCC cases, we detected 5351 total nonsynonymous mutations, of which 356 mutations were previously reported in the COSMIC database (Supplemental Table S6 ).
MCPyV-negative tumors demonstrated markedly higher mutation rate per megabase than in PIK3CA mutations were present in three tumors, two of which were activating (E545K and K111E) (1, 20) . Interestingly, in two cases we also identified mutations novel to MCC in KNSTRN, a kinetochore gene recently reported to undergo oncogenic mutation in 19% of cutaneous squamous cell carcinomas (SCC) (21) . Similar to SCC, KNSTRN mutations in MCC resided in the N-terminus, including a S24F hotspot mutation. One MCPyV-positive tumor harbored two separate HRAS mutations (G12C and G13D) in distinct subclones (Supplemental PRUNE2 and NOTCH1 mutations have not been described in MCC. PRUNE2, a proapoptotic factor (24) , is mutated in 20% of melanomas (The Cancer Genome Atlas). We identified two inactivating mutations in the glutamate receptor subunit GRIN2A (2/8, 25%): a splice site mutation and the (R902K) loss-of-function mutation described in melanoma (25) Tables S6-S7) . Further, we discovered a novel missense mutation in the DNA damage response gene BRCA2 (D2819V) affecting the DNA binding domain (Supplemental Table S6 ).
Interestingly, mutations affecting one or more NOTCH genes were identified in 6/8 (75%) MCPyV-negative MCCs (Figure 3, Supplemental Tables S6-S7) . NOTCH mutations in MCC were mainly located in EGF or ankyrin repeat regions, consistent with inactivating mutations (Figure 4) . We independently validated the somatic mutation calls by PCR-Sanger sequencing and confirmed the presence of NOTCH mutations in tumors but not in the matched normal samples for 16 of 17 mutations (Supplemental Table S7 ). The majority of mutations were C>T transitions at dipyrimidine sites. Depending on cancer type, NOTCH signaling may play either an oncogenic or tumor suppressor role (26, 27) . In hematologic malignancies,
NOTCH mutations or fusions that disrupt the C-terminal PEST domain result in increased
NOTCH stability and aberrant signaling that promotes tumorigenesis. However, NOTCH signaling plays a tumor suppressor role in squamous cell carcinoma (SCC) and small cell lung carcinoma (26, 27) . The clustering of NOTCH mutations in EGF and ankyrin repeat domains in our MCC cohort is consistent with loss-of-function events, suggesting that NOTCH signaling plays a tumor suppressor role in MCC similar to other neuroendocrine malignancies.
Insertion/deletion analysis (indels) identified 32 indels (Supplemental Table S8 ). One tumor harbored an activating frameshift deletion at exon 6 in PPM1D, a negative regulator of p53 (28) . Another tumor harbored a frameshift deletion of the DNA damage response gene ATM that is predicted to be inactivating due to loss of the kinase domain.
Fusion analysis revealed a total of 15 calls but no predicted oncogenic driver events were noted (Supplemental Table S9 ). However, we did identify a highly expressed fusion transcript in MCC_456 between MLH1 and SPATA4 (Supplemental Figure S4A) . This fusion results in Figure S4B) . We independently confirmed this fusion by Sanger sequencing of the fusion PCR product from the index sample (Supplemental Figure S4C) . In addition, SPATA4 expression was restricted to the index sample, indicating 3' partner expression driven by the underlying causal fusion event (Supplemental Figure S4D-E) . The functional significance of the fusion gene remains to be characterized. 
